Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

Table 3 Factors associated with rituximab response in the combination cohort (cohorts 1 and 2)

Characteristics		EULAR non-responders (n = 47)	EULAR responders (n = 138)	Univariate OR (95% CI)	p value	Multivariate OR (95% CI)	p value
DAS28-CRP	3.2–5.1 (Ref)	26 (40.6%)	38 (59.4%)	3.26 (1.64–6.47)	0.0007	4.10 (1.90–8.85)	0.0003
DAS28-CRP	>5.1	21 (17.4%)	100 (82.6%)	3.26 (1.64–6.47)	0.0007	4.10 (1.90–8.85)	0.0003
RF or anti-CCP	Negative (Ref)	9 (47.4%)	10 (52.6%)	3.03 (1.15–8.001)	0.025	3.27 (1.13–9.46)	0.03
RF or anti-CCP	Positive	38 (22.9%)	128 (77.1%)	3.03 (1.15–8.001)	0.025	3.27 (1.13–9.46)	0.03
IgG > ULN (g/L)	No (Ref)	36 (33.3%)	72 (66.7%)	2.55 (1.16–5.60)	0.02	2.32 (1.01–5.33)	0.048
IgG > ULN (g/L)	Yes	10 (16.4%)	51 (83.6%)	2.55 (1.16–5.60)	0.02	2.32 (1.01–5.33)	0.048
Detectable IL-33	No (Ref)	37 (30.1%)	86 (69.9%)	2.24 (1.03–4.87)	0.04	2.40(1.01–5.72)	0.047
Detectable IL-33	Yes	10 (16.1%)	52 (83.9%)	2.24 (1.03–4.87)	0.04	2.40(1.01–5.72)	0.047

Values are given as n (%) of responders or non-responders with a given characteristic
Rituximab response was evaluated at week 24 according to EULAR response
anti-CCP anti-cyclic citrullinated peptide antibody, CI confidence interval, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, EULAR European League Against Rheumatism, Ig immunoglobulin, OR odds ratio, Ref referent, RF rheumatoid factor, ULN upper limit of normal (i.e., 12.7 g/L)

ISSN: 1478-6362